Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Fluorouracil 14Radiotherapy 11Mitomycin 9Radiation 8Capecitabine 8Surveys and Questionnaires 6Drug Therapy 6Cisplatin 6pembrolizumab 5Paclitaxel 4Magnetic Resonance Spectroscopy 4Irinotecan 3Immune Checkpoint Inhibitors 3Cetuximab 3Carboplatin 3Biopsy 3tislelizumab 2durvalumab 2atezolizumab 2aldesleukin 2Therapeutics 2Specimen Handling 2Papillomavirus Vaccines 2Oxaliplatin 2Observation 2Nivolumab 2Cyclophosphamide 2Blood Specimen Collection 2Adoptive Transfer 2toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anus Neoplasms × MEDI0457 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡